NO2877697T3 - - Google Patents

Info

Publication number
NO2877697T3
NO2877697T3 NO13823572A NO13823572A NO2877697T3 NO 2877697 T3 NO2877697 T3 NO 2877697T3 NO 13823572 A NO13823572 A NO 13823572A NO 13823572 A NO13823572 A NO 13823572A NO 2877697 T3 NO2877697 T3 NO 2877697T3
Authority
NO
Norway
Application number
NO13823572A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2877697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2877697T3 publication Critical patent/NO2877697T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO13823572A 2012-04-20 2013-07-29 NO2877697T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
NO2877697T3 true NO2877697T3 (pl) 2018-10-13

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13823572A NO2877697T3 (pl) 2012-04-20 2013-07-29

Country Status (47)

Country Link
US (8) US20140018391A1 (pl)
EP (3) EP2838892B1 (pl)
JP (3) JP6109925B2 (pl)
KR (2) KR101972998B1 (pl)
CN (3) CN103857669B (pl)
AP (1) AP2014008013A0 (pl)
AR (1) AR090725A1 (pl)
AU (1) AU2013249197B2 (pl)
BR (1) BR112014025972A8 (pl)
CA (2) CA2869893C (pl)
CL (1) CL2014002817A1 (pl)
CO (1) CO7131356A2 (pl)
CR (1) CR20140530A (pl)
CY (1) CY1120276T1 (pl)
DK (2) DK2838892T3 (pl)
DO (1) DOP2014000235A (pl)
EA (1) EA031581B1 (pl)
EC (1) ECSP14027739A (pl)
ES (2) ES2820354T3 (pl)
GE (1) GEP20186902B (pl)
HK (2) HK1202863A1 (pl)
HR (1) HRP20180316T1 (pl)
HU (2) HUE050865T2 (pl)
IL (1) IL235064B (pl)
JO (1) JO3353B1 (pl)
LT (1) LT2838892T (pl)
MA (1) MA37524B1 (pl)
MD (1) MD4615C1 (pl)
ME (1) ME02966B (pl)
MX (1) MX354793B (pl)
MY (1) MY170068A (pl)
NI (1) NI201400124A (pl)
NO (1) NO2877697T3 (pl)
NZ (1) NZ700833A (pl)
PE (1) PE20150084A1 (pl)
PH (1) PH12014502351A1 (pl)
PL (2) PL2838892T3 (pl)
PT (2) PT2838892T (pl)
RS (1) RS56869B1 (pl)
SG (2) SG11201406478XA (pl)
SI (2) SI3290410T1 (pl)
TN (1) TN2014000421A1 (pl)
TW (2) TWI589572B (pl)
UA (1) UA116207C2 (pl)
UY (1) UY34753A (pl)
WO (1) WO2013158874A1 (pl)
ZA (1) ZA201408508B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN113577074A (zh) * 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
MA43294A1 (fr) 2015-07-24 2020-04-30 Newlink Genetics Corp Sels et promédicaments de 1-méthyl -d-tryptophane
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
WO2005030698A1 (en) * 2003-09-26 2005-04-07 Ranbaxy Laboratories Limited Process for the preparation of voglibose
MXPA06015003A (es) 2004-06-29 2007-08-07 Sapphire Therapeutics Inc Formas cristalinas de 1,2,2-trimetilhidrazida de acido (3r)-1-(2-metilalanil-d-triptofil)-3-(fenilmetil)-3- piperidincarboxilico.
AU2008216789A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
US20150072934A1 (en) 2015-03-12
EP3517532B1 (en) 2021-10-13
WO2013158874A1 (en) 2013-10-24
MD4615C1 (ro) 2019-08-31
US9872883B2 (en) 2018-01-23
CN103857669A (zh) 2014-06-11
EP2838892A1 (en) 2015-02-25
ES2820354T3 (es) 2021-04-20
EP3290410B1 (en) 2020-07-01
US9403867B2 (en) 2016-08-02
CA3031652A1 (en) 2013-10-24
AU2013249197A1 (en) 2014-10-30
HK1202863A1 (en) 2015-10-09
UY34753A (es) 2013-11-29
KR20150013115A (ko) 2015-02-04
RS56869B1 (sr) 2018-04-30
SI2838892T1 (en) 2018-05-31
DK2838892T3 (en) 2018-03-12
US20190000914A1 (en) 2019-01-03
PT2838892T (pt) 2018-02-28
TWI589572B (zh) 2017-07-01
JP2018076375A (ja) 2018-05-17
CY1120276T1 (el) 2019-07-10
BR112014025972A2 (pt) 2017-06-27
EA201401151A1 (ru) 2015-06-30
PT3517532T (pt) 2021-11-08
NZ700833A (en) 2016-01-29
US20140018391A1 (en) 2014-01-16
HUE050865T2 (hu) 2021-01-28
CN103857669B (zh) 2019-06-28
US20190231843A1 (en) 2019-08-01
US20160229889A1 (en) 2016-08-11
ECSP14027739A (es) 2015-12-31
US20160237115A1 (en) 2016-08-18
US10905737B2 (en) 2021-02-02
JP2015514779A (ja) 2015-05-21
IL235064A0 (en) 2014-12-31
JO3353B1 (ar) 2019-03-13
CA2869893A1 (en) 2013-10-24
CA3031652C (en) 2020-10-27
TWI677494B (zh) 2019-11-21
NI201400124A (es) 2015-09-21
SG11201406478XA (en) 2014-11-27
PH12014502351B1 (en) 2015-01-12
EP2838892B1 (en) 2017-12-06
JP6284665B2 (ja) 2018-02-28
CR20140530A (es) 2015-03-25
DK3517532T3 (da) 2022-01-03
KR20190044697A (ko) 2019-04-30
US20160235804A1 (en) 2016-08-18
KR101972998B1 (ko) 2019-04-29
TW201722928A (zh) 2017-07-01
EP3290410A1 (en) 2018-03-07
CO7131356A2 (es) 2014-12-01
ME02966B (me) 2018-07-20
EP3517532A1 (en) 2019-07-31
HRP20180316T1 (hr) 2018-04-06
MA37524B1 (fr) 2017-04-28
MA37524A1 (fr) 2016-06-30
AR090725A1 (es) 2014-12-03
CA2869893C (en) 2019-03-05
JP6616853B2 (ja) 2019-12-04
TN2014000421A1 (en) 2016-03-30
JP6109925B2 (ja) 2017-04-05
HUE035697T2 (en) 2018-05-28
SG10201608488RA (en) 2016-12-29
EA031581B1 (ru) 2019-01-31
HK1248694A1 (zh) 2018-10-19
KR102141323B1 (ko) 2020-08-05
IL235064B (en) 2019-09-26
ES2658862T3 (es) 2018-03-12
MY170068A (en) 2019-07-03
MD20140122A2 (ro) 2015-05-31
CN110041304A (zh) 2019-07-23
US9981002B2 (en) 2018-05-29
AU2013249197B2 (en) 2017-04-06
AP2014008013A0 (en) 2014-10-31
PE20150084A1 (es) 2015-01-23
MX354793B (es) 2018-03-21
MX2014012178A (es) 2015-08-05
US10576122B2 (en) 2020-03-03
SI3290410T1 (sl) 2020-11-30
DOP2014000235A (es) 2015-01-31
TW201348224A (zh) 2013-12-01
US9956261B2 (en) 2018-05-01
BR112014025972A8 (pt) 2021-06-22
JP2017101082A (ja) 2017-06-08
CN110041398A (zh) 2019-07-23
US20200276259A1 (en) 2020-09-03
PL2838892T3 (pl) 2018-05-30
LT2838892T (lt) 2018-03-12
PL3290410T3 (pl) 2021-01-11
GEP20186902B (en) 2018-10-25
US10300105B2 (en) 2019-05-28
PH12014502351A1 (en) 2015-01-12
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
UA116207C2 (uk) 2018-02-26
CL2014002817A1 (es) 2015-08-14

Similar Documents

Publication Publication Date Title
BR112014017635A2 (pl)
BR112014017614A2 (pl)
BR112014017592A2 (pl)
BR112014017625A2 (pl)
BR112014017659A2 (pl)
BR112014017638A2 (pl)
AR092201A1 (pl)
BR112014017607A2 (pl)
BR112013027865A2 (pl)
BR112014017634A2 (pl)
BR112014017609A2 (pl)
BR112014017644A2 (pl)
BR112014017647A2 (pl)
BR112014017588A2 (pl)
BR112014017618A2 (pl)
BR112014013184A8 (pl)
BR112014017630A2 (pl)
BR112014017652A2 (pl)
BR112014017621A2 (pl)
BR112014017622A2 (pl)
BR112014017627A2 (pl)
BR112014017623A2 (pl)
BR112014017641A2 (pl)
BR112014017631A2 (pl)
BR112014017636A2 (pl)